Recently, the TAR DNA binding protein 43 (TDP-43) has been shown to be present in neuronal inclusions in frontotemporal lobar degeneration with ubiquitin-immunoreactive inclusions (FTLD-U), as well as in amyotrophic lateral sclerosis (ALS) [17] . TDP-43, a nuclear DNA binding protein that is involved in transcriptional regulation, is aberrantly deposited in Wlamentous cytoplasmic inclusions subsequent to a series of post-translational modiWcations including proteolysis, phosphorylation and ubiquitination [17] . Neuronal cytoplasmic inclusions have been known to be a consistent feature of motor neuron degeneration in ALS for over a decade [12, 14] , but their molecular composition was not known. Prior to this discovery, the motor neuron inclusions of ALS were only known to be immunoreactive for ubiquitin [12, 14] and the ubiquitin-binding protein p62/sequestosome [15] , but these markers are not disease speciWc and can be detected in inclusions in a wide range of other disorders as well as inclusions and other pathology in the normal aged brain. Consequently, it was diYcult to determine what was disease speciWc in these cases, especially for inclusions that were present in extramotor regions of the nervous system. This problem has apparently been resolved with the discovery of TDP-43, which has been suggested to be a speciWc marker for ALS. It is present in the neuronal (and glia) inclusions in all cases of ALS that have been studied, except for those that are found in the setting of familial ALS due to mutations in the superoxide dismutase-1 gene [13, 19] . At present it is unknown if TDP-43 will be present in inclusions in familial ALS due to mutations in other genes.
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Degeneration of upper or lower motor neurons, or both (as in ALS), occurs in a wide range of other disorders, including frontotemporal lobar degeneration with motor neuron disease (FTLD-MND) and Guam ALS and Parkinson dementia complex (PDC). Guam PDC is a neurodegenerative disorder associated with neuroWbrillary tangles in widespread parts of the central nervous system [11] . In some patients, PDC is accompanied by clinical features of ALS. The pathogenesis of ALS on Guam has been debated over the years [10] . One school favored the idea that ALS was due to neuroWbrillary pathology aVecting motor neurons similar to pathology aVecting higher cortical areas and correlating with dementia or pathology in the substantia nigra and correlating with Parkinsonism. The other school favored the idea that ALS on Guam was an independent disease process similar to ALS that occurred in other settings [18] . The relative speciWcity of TDP-43 has been used to study ALS that occurs on Guam in the study by Geser et al. [7] in this issue of Acta Neuropathologica. Spinal cord pathology was studied in a group of cases of ALS, PDC and normal controls from Guam. The motor neuron pathology was similar to that in sporadic ALS [7] . In non-motor areas neuroWbrillary pathology predominated, as expected, in PDC, while the spinal cord in PDC had only sparse TDP-43-immunoreactive motor neuron pathology. These observations would tend to support the dual hypothesis that ALS and PDC are independent disease processes.
On the other hand, TDP-43 pathology has also been reported in neurons (and glia) in PDC cases that have not had motor neuron pathology [8] . This might argue for the unitary hypothesis in which PDC is associated with both neuroWbrillary and TDP-43 pathology. On the other hand, even in non-Guamanian ALS cases, neuronal inclusions have been reported outside the motor system and these are clearly unrelated to concurrent neuroWbrillary pathology.
In another report in this issue of Acta Neuropathologica, Zhang et al. [21] have shown that TDP-43-immunoreactive inclusions are common in the basal ganglia in ALS with and without dementia, although they tended to be more numerous in cases with dementia. Cases with ALS-dementia in that report are similar to what other investigators refer to as FTLD-MND. In a third paper in Acta Neuropathologica, Brandmeir et al. [3] have also shown widespread cortical and subcortical TDP-43-immunoreactive pathology in FTLD-MND. The Wndings from these two studies suggest that ALS and FTLD-MND are part of a common disease spectrum [4] , and that while motor neurons are aVected, there is more widespread cortical and subcortical pathology in this disorder.
Crucial to this debate is the speciWcity of TDP-43 for the disease spectrum deWned by FTLD-U, FTLD-MND and ALS. While the initial studies from Neumann et al. [17] did not detect TDP-43 in a range of other neuropathologic conditions, more recently this view has been challenged. The Wrst report that TDP-43 may not be speciWc for FTLD-U, FTLD-MND and ALS was from Arai et al. [2] who showed that TDP-43-immunoreactivity was present in some cases of Pick's disease. Subsequently, Amador-Ortiz et al. [1] found TDP-43 immunoreactivity in 20% of Alzheimer cases and over 70% of cases of hippocampal sclerosis. While Alzheimer type pathology and hippocampal sclerosis might be expected in some cases of FTLD-U, especially late-onset FTLD-U, none of the Alzheimer cases in that series had any evidence of motor neuron disease. Moreover, TDP-43 was clearly shown to co-localize with neuroWbrillary tangles in a subset of Alzheimer cases [1] , raising the possibility that it may be co-deposited with other disease-related proteins, analogous to the known co-deposition of -synuclein and tau in a subset of neurons in Alzheimer's disease [20] . More recently, two groups have reported that TDP-43 co-localizes occasionally with -synuclein in Lewy body disease [9, 16] .
How a nuclear protein is deposited as cytoplasmic inclusions in FTLD-U, FTLD-MND, and ALS remains a mystery, but clues to the mechanism have come from recent cell culture experiments, in which it has been shown that TDP-43 can be cleaved by caspases, which are active during programmed cell death [22] . That programmed cell death is felt to play a critical role in many neurodegenerative disorders. Programmed cell death mechanisms may also lead to post-translational modiWcations in TDP-43 that promote its deposition in inclusions may provide a clue as to why inclusions of this type are detected in only a subset of neurodegenerative disorders. The generation of cleaved protein fragments that have abnormal solubility properties and that aggregate can also play a role in neurodegeneration by interfering with protein degradation mechanisms. The interplay between protein degradation pathways and programmed cell death has been the focus of increasing research in recent years [5] . Interestingly, it has been shown that disruption of both ubiquitin proteasomal and autophagic pathways lead to aberrant accumulation of cytoplasmic TDP-43 [6, 22] . These Wndings caution one to think of TDP-43 as being disease speciWc any more than a given molecular mechanism is disease speciWc. More likely, TDP-43 pathology will be a manifestation of a limited number of disorders that share common disease mechanisms. Neuropathologic characterization of a range of disorders with TDP-43 inclusions, which at present include FTLD-U, FTLD-MND, ALS, Guam PDC, Alzheimer's disease, hippocampal sclerosis, and Lewy body disease, will lead to a clearer understanding of pathogenesis and etiology of these disorders.
